Company intelligence / Profile preview

Pimera Therapeutics

Rockville, Maryland, United Statesprimeratherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Primera Therapeutics is developing gene editing therapeutics for mitochondrial diseases. The company currently has programs in the discovery phase, including PTX-101 and MGE-101.

Therapeutic areas: Rare DiseasesNephrology
Modalities: Gene editing therapeuticsTALE-based gene editing system
Industry: Biotech

Partnerships

CellectisMayo ClinicCHOPUMDF

Beyond the preview

Go deeper on Pimera Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pimera Therapeutics.

Explore the full profile